Covers enzyme inhibition mechanisms, drug modes of action, targeted protein degradation using PROTACs, and the bump-hole method for protein-ligand engineering.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Explores the selection and rationale behind preclinical animal models in drug discovery, emphasizing understanding mechanisms of action and domain specificity.